Second-line modified FOLFIRINOX for patients with unresectable advanced pancreatic cancer after first-line gemcitabine plus nab-paclitaxel failure
Not Applicable
Recruiting
- Conditions
- The unresectable advanced pancreatic cancer after first-line nab-Paclitaxel plus Gemcitabine failure
- Registration Number
- JPRN-UMIN000038211
- Lead Sponsor
- Aichi Medical University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 45
Inclusion Criteria
Not provided
Exclusion Criteria
1) Patients with contraindication of FOLFIRINOX 2) Second primary malignancy 3) Any patients judged by the investigator to be unfit to participate in the study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Progression free survival
- Secondary Outcome Measures
Name Time Method Disease control rate Overall survival Response rate Adverse event relative dose intensity